Skip to main
LPCN
LPCN logo

Lipocine (LPCN) Stock Forecast & Price Target

Lipocine (LPCN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lipocine Inc. has a promising outlook due to the potential regulatory approval and commercialization of its oral testosterone replacement therapy, TLANDO, in Canada, which is expected to enhance the company's topline revenue significantly. Additionally, the promising results from LPCN 1154, an innovative formulation for postpartum depression with a rapid onset of action and impressive remission rates in clinical trials, position Lipocine advantageously within a niche market with notable unmet medical needs. Furthermore, management has identified limited promotional activities for existing testosterone replacement therapies in Canada, suggesting that TLANDO could capture substantial market share, bolstered by a recent exclusive licensing agreement for TLANDO in the U.S. with Verity.

Bears say

Lipocine Inc. reported a net loss of $3.2 million for the third quarter of 2025, highlighting the ongoing financial challenges faced by the company. The company is currently relying on the upcoming Phase 3 PPD trial for LPCN 1154, which poses significant risks, including potential failure in clinical trials, regulatory approval, and market competition. Additionally, concerns about dilution risk further compound the negative outlook for Lipocine, as these factors could adversely affect the company’s financial stability and future growth prospects.

Lipocine (LPCN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lipocine (LPCN) Forecast

Analysts have given Lipocine (LPCN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Lipocine (LPCN) has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lipocine (LPCN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.